JP3693916B2 - 新規なジヒドロキシヘキサン酸誘導体 - Google Patents

新規なジヒドロキシヘキサン酸誘導体 Download PDF

Info

Publication number
JP3693916B2
JP3693916B2 JP2000530493A JP2000530493A JP3693916B2 JP 3693916 B2 JP3693916 B2 JP 3693916B2 JP 2000530493 A JP2000530493 A JP 2000530493A JP 2000530493 A JP2000530493 A JP 2000530493A JP 3693916 B2 JP3693916 B2 JP 3693916B2
Authority
JP
Japan
Prior art keywords
methyl
amide
carboxylic acid
dihydroxy
octyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000530493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502839A (ja
Inventor
キャス,ジョン・チャールズ
ブラウン,マシュー・フランク
ポス,クリストファー・スタンリー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2002502839A publication Critical patent/JP2002502839A/ja
Application granted granted Critical
Publication of JP3693916B2 publication Critical patent/JP3693916B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
JP2000530493A 1998-02-05 1999-01-18 新規なジヒドロキシヘキサン酸誘導体 Expired - Lifetime JP3693916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05
US60/073,801 1998-02-05
PCT/IB1999/000067 WO1999040061A2 (en) 1998-02-05 1999-01-18 Novel dihydroxyhexanoic acid derivatives

Publications (2)

Publication Number Publication Date
JP2002502839A JP2002502839A (ja) 2002-01-29
JP3693916B2 true JP3693916B2 (ja) 2005-09-14

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000530493A Expired - Lifetime JP3693916B2 (ja) 1998-02-05 1999-01-18 新規なジヒドロキシヘキサン酸誘導体

Country Status (36)

Country Link
EP (1) EP1051405B1 (OSRAM)
JP (1) JP3693916B2 (OSRAM)
KR (1) KR100385529B1 (OSRAM)
CN (1) CN1177834C (OSRAM)
AP (1) AP992A (OSRAM)
AR (1) AR016175A1 (OSRAM)
AT (1) ATE337307T1 (OSRAM)
AU (1) AU752407B2 (OSRAM)
BG (1) BG104726A (OSRAM)
BR (1) BR9907655A (OSRAM)
CA (1) CA2320388C (OSRAM)
DE (1) DE69932920T2 (OSRAM)
DZ (1) DZ2717A1 (OSRAM)
EA (1) EA003137B1 (OSRAM)
ES (1) ES2268847T3 (OSRAM)
GT (1) GT199900011A (OSRAM)
HR (1) HRP20000529B1 (OSRAM)
HU (1) HUP0100832A3 (OSRAM)
IL (1) IL137330A0 (OSRAM)
IS (1) IS5562A (OSRAM)
MA (1) MA26603A1 (OSRAM)
MY (1) MY133125A (OSRAM)
NO (1) NO20003965D0 (OSRAM)
NZ (1) NZ505724A (OSRAM)
OA (1) OA11448A (OSRAM)
PA (1) PA8467301A1 (OSRAM)
PE (1) PE20000243A1 (OSRAM)
PL (1) PL342817A1 (OSRAM)
SK (1) SK11262000A3 (OSRAM)
TN (1) TNSN99013A1 (OSRAM)
TR (1) TR200002248T2 (OSRAM)
TW (1) TW470744B (OSRAM)
UA (1) UA57824C2 (OSRAM)
WO (1) WO1999040061A2 (OSRAM)
YU (1) YU47100A (OSRAM)
ZA (1) ZA99873B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044365A1 (en) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
DE60039115D1 (de) * 1999-08-20 2008-07-17 Dow Agrosciences Llc Fungizide heterocyclische aromatische amide und deren zusammensetzungen, verfahren zu deren anwendung und herstellung
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
EE200200432A (et) 2000-02-04 2003-12-15 Pfizer Products Inc. Heterotsüklilised amiidderivaadid
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
BR0210519A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de adsorvatos de fármaco amorfo
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2003223050A1 (en) * 2002-05-14 2003-11-11 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
CA2484860A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
MXPA05001781A (es) * 2002-08-12 2005-04-25 Pfizer Prod Inc Formas cristalinas de [4-carbamoil -1-(3- fluorobencil)-2, 7-dihidroxi- 7-metil- octil]-amida del acido quinoxalina-2- carboxilico.
PT1530457E (pt) 2002-08-12 2009-11-06 Bend Res Inc Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
CA2532931A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
ES2180600T3 (es) * 1994-10-19 2003-02-16 Novartis Ag Eteres de isosteros substrato de aspartato proteasa antivirales.
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
OA11448A (en) 2003-11-18
IL137330A0 (en) 2001-07-24
EA003137B1 (ru) 2003-02-27
BG104726A (en) 2001-04-30
EA200000741A1 (ru) 2001-02-26
ZA99873B (en) 2000-08-04
NO20003965L (OSRAM) 2000-10-03
TW470744B (en) 2002-01-01
AP9901457A0 (en) 1999-03-31
ES2268847T3 (es) 2007-03-16
BR9907655A (pt) 2000-10-24
MA26603A1 (fr) 2004-12-20
TNSN99013A1 (fr) 2005-11-10
AU752407B2 (en) 2002-09-19
EP1051405B1 (en) 2006-08-23
DE69932920T2 (de) 2007-02-08
JP2002502839A (ja) 2002-01-29
WO1999040061A3 (en) 1999-10-21
DZ2717A1 (fr) 2003-09-01
PL342817A1 (en) 2001-07-02
PE20000243A1 (es) 2000-04-07
MY133125A (en) 2007-10-31
AP992A (en) 2001-08-06
CA2320388A1 (en) 1999-08-12
CA2320388C (en) 2005-05-03
KR100385529B1 (ko) 2003-05-27
NO20003965D0 (no) 2000-08-04
IS5562A (is) 2000-07-14
AU1778999A (en) 1999-08-23
HUP0100832A2 (hu) 2002-02-28
WO1999040061A2 (en) 1999-08-12
YU47100A (sh) 2002-11-15
KR20010040684A (ko) 2001-05-15
HK1034969A1 (en) 2001-11-09
AR016175A1 (es) 2001-06-20
CN1290255A (zh) 2001-04-04
CN1177834C (zh) 2004-12-01
HUP0100832A3 (en) 2002-03-28
NZ505724A (en) 2003-02-28
ATE337307T1 (de) 2006-09-15
UA57824C2 (uk) 2003-07-15
PA8467301A1 (es) 2000-05-24
GT199900011A (es) 2000-07-20
EP1051405A2 (en) 2000-11-15
DE69932920D1 (de) 2006-10-05
HRP20000529B1 (en) 2004-12-31
HRP20000529A2 (en) 2001-08-31
SK11262000A3 (sk) 2001-01-18
TR200002248T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
JP3693916B2 (ja) 新規なジヒドロキシヘキサン酸誘導体
US11286256B2 (en) Bicyclic inhibitors of histone deacetylase
EP1691814B1 (en) Anti-inflammatory agents
DE60133273T2 (de) Inhibitoren von peptid deformylase
US6673801B1 (en) Dihydroxyhexanoic acid derivatives
US20040133001A1 (en) Peptide deformylase inhibitors
HK1034969B (en) Dihydroxyhexanoic acid derivatives
MXPA00007690A (en) Novel dihydroxyhexanoic acid derivatives
NZ523610A (en) A method of treating inflammatory conditions in a non-human mammal comprising administration of dihydroxyhexanoic acid derivatives
CZ20002760A3 (cs) Nové deriváty dihydroxyhexanové kyseliny a farmaceutický prostředek, který je obsahuje
US6858744B2 (en) Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
HK40020413B (en) Bicyclic inhibitors of histone deacetylase
HK40020413A (en) Bicyclic inhibitors of histone deacetylase
HK1094680B (en) Anti-inflammatory agents

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20040319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050622

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080701

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090701

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100701

Year of fee payment: 5